Bioscience Vaccines Inc. has received a $400,000 seed investment to develop technology that enhances the effectiveness of vaccines.
Bioscience Vaccines will use the funding to prepare for a Phase 1 human clinical trial. The company no doubt hopes that recent publicity surrounding vaccines for H1N1 will help it draw attention from additional investors.
The funding comes from BioCrossroads, a state-sponsored group that promotes the life sciences industry in Indiana, according to a statement from the organization.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company is developing what’s known as an adjuvant, a substance added to a vaccine to improve the immune response so that less vaccine is needed to provide protection. The adjuvant is based on “extracellular matrix” technology Bioscience Vaccines licensed from Cook Biotech, a company founded in 1995 that built on research conducted at Purdue University. The technology uses cells derived from pigs’ small intestines to help the human body repair itself by attracting new cells and facilitating tissue regeneration.
Bioscience Vaccines says it has data showing its adjuvant can boost the potency of tetanus vaccine by 10 to 15 times in laboratory models, according to the statement.
The company’s chief science officer, Mark Suckow, directs the University of Notre Dame’s life sciences center. Accordingly, Biosciences Venture is in discussions about moving its headquarters to Notre Dame’s campus in South Bend, Ind.
Chief Executive Paul Hall wasn’t immediately available for comment.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company sees plenty of market potential for its adjuvant. Biosciences Vaccines said human vaccines are expected to be a $24 billion market in two years, and the veterinary vaccine market will account for another $4 to $5 billion.
